Ionis Pharmaceuticals received FDA approval for Dawnzera (donidalorsen), a prophylactic antisense therapy for hereditary angioedema (HAE), a rare genetic condition causing painful swelling episodes. Clinical trials demonstrated an 81% reduction in attack frequency compared to placebo, with potential dosing intervals of four to eight weeks. The approval positions Dawnzera amid an existing competitive market with established therapies and ongoing developments.